Rates of major depressive symptoms are elevated after acute infection with SARS-CoV-2.1- 3 A key question is whether such symptoms represent a general consequence of stress associated with acute illness or whether they reflect more specific sequelae associated with COVID-19 pathophysiology itself. To examine this possibility, in this survey study, we compared features of major depression in individuals with or without prior COVID-19 illness.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accepted for Publication: May 7, 2021.
Published: June 11, 2021. doi:10.1001/jamanetworkopen.2021.16612
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Perlis RH et al. JAMA Network Open.
Corresponding Author: Roy H. Perlis, MD, MSc, Departmentof Psychiatry, Massachusetts General Hospital, 185 Cambridge St, 6th Fl, Boston, MA 02114 (email@example.com).
Author Contributions: Dr Perlis had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Perlis, Green, Lazer.
Acquisition, analysis, or interpretation of data: Perlis, Santillana, Ognyanova, Druckman, Lazer, Baum.
Drafting of the manuscript: Perlis.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Perlis, Santillana, Ognyanova.
Obtained funding: Ognyanova, Lazer, Baum.
Administrative, technical, or material support: Ognyanova, Druckman, Lazer.
Conflict of Interest Disclosures: Dr Perlis reported receiving consulting fees from Burrage Capital, Genomind, RID Ventures, and Takeda; receiving personal fees from Belle Artificial Intelligence; and holding equity in Outermost Therapeutics and Psy Therapeutics. No other disclosures were reported.
Funding/Support: This study was supported by the National Institute of Mental Health (grant R01MH116270 to Dr Perlis), the Blyth Family Fund, and the National Science Foundation (support to Drs Ognyanova, Lazar, and Baum).
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: Dr Perlis is an associate editor for JAMA Network Open but was not involved in the editorial review or decision process for this manuscript.
You currently have no searches saved.
You currently have no courses saved.